CL2020002550A1 - Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos. - Google Patents

Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos.

Info

Publication number
CL2020002550A1
CL2020002550A1 CL2020002550A CL2020002550A CL2020002550A1 CL 2020002550 A1 CL2020002550 A1 CL 2020002550A1 CL 2020002550 A CL2020002550 A CL 2020002550A CL 2020002550 A CL2020002550 A CL 2020002550A CL 2020002550 A1 CL2020002550 A1 CL 2020002550A1
Authority
CL
Chile
Prior art keywords
pharmaceutical use
pyrazole compounds
heteroaryl substituted
substituted pyrazole
pharmaceutical
Prior art date
Application number
CL2020002550A
Other languages
English (en)
Inventor
Tomoya Miura
Shintaro Hirashima
Tomoyuki Manabe
Tetsuya Iida
Kentaro Sakurai
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of CL2020002550A1 publication Critical patent/CL2020002550A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos de pirazol sustituidos con heteroarilo o sus sales farmacéuticamente<br /> aceptables que tienen una actividad inhibidora de SGLT1 y son útiles para un fármaco, composiciones farmacéuticas que lo comprenden, y su uso farmacéutico; específicamente, un compuesto de fórmula [X]:<br /> en donde R1 es hidrógeno o halógeno, R2 es alquilo de C1-6 o haloalquilo de C1-6, el anillo Het es piridilo sustituido o pirazinilo, pirimidinilo o piridazinilo opcionalmente sustituido, o una sal farmacéuticamente aceptable del mismo, una composición farmacéutica que lo comprende, y su uso farmacéutico se proporciona.
CL2020002550A 2018-04-04 2020-10-01 Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos. CL2020002550A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018072557 2018-04-04

Publications (1)

Publication Number Publication Date
CL2020002550A1 true CL2020002550A1 (es) 2021-01-15

Family

ID=68100257

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002550A CL2020002550A1 (es) 2018-04-04 2020-10-01 Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos.

Country Status (19)

Country Link
US (3) US10988462B2 (es)
EP (1) EP3778593A4 (es)
JP (3) JP7130588B2 (es)
KR (1) KR20200139696A (es)
CN (1) CN111902408B (es)
AR (1) AR114465A1 (es)
AU (1) AU2019249560B2 (es)
BR (1) BR112020019939A2 (es)
CA (1) CA3089092A1 (es)
CL (1) CL2020002550A1 (es)
CO (1) CO2020012353A2 (es)
IL (1) IL277686A (es)
MX (1) MX2020010433A (es)
PE (1) PE20201068A1 (es)
PH (1) PH12020551624A1 (es)
SG (1) SG11202009179TA (es)
TW (1) TWI805727B (es)
WO (1) WO2019194207A1 (es)
ZA (1) ZA202006053B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
SG11202009179TA (en) * 2018-04-04 2020-10-29 Japan Tobacco Inc Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof
KR20220056219A (ko) * 2019-09-04 2022-05-04 니뽄 다바코 산교 가부시키가이샤 병용 의약에 의한 당뇨병의 치료 또는 예방 방법
BR112022003497A2 (pt) * 2019-09-04 2022-05-17 Japan Tobacco Inc Método de tratamento ou prevenção de doença renal crônica
US20230321044A1 (en) * 2020-03-19 2023-10-12 Japan Tobacco Inc. Treatment or prevention method for chronic heart failure

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH04247081A (ja) 1991-02-01 1992-09-03 Takeda Chem Ind Ltd ５員複素環酸アミド類
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
CA2515119A1 (en) 2003-02-07 2004-08-19 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivative
AU2004200420A1 (en) 2003-03-11 2004-09-30 Astellas Pharma Inc. Inhibitor of cyclooxygenase
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd ７員複素環誘導体
WO2004110351A2 (en) 2003-05-14 2004-12-23 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis c virus
US7576064B2 (en) * 2003-06-20 2009-08-18 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, drug composition containing the same and production intermediate therefor
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
TW200526641A (en) 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
DE102004028241B4 (de) * 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
EP1765335B1 (en) 2004-07-07 2009-11-25 Merck & Co., Inc. Pyrazole amide derivatives, compositions containing such compounds and methods of use
WO2006054057A2 (en) 2004-11-16 2006-05-26 Gw Pharma Limited New use for cannabinoid
ATE439347T1 (de) * 2004-11-23 2009-08-15 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptansäure- derivate als hmg-co-a-reductase-inhibitoren zur behandlung von lipidemia
JP2008007405A (ja) 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
CA2610172A1 (en) 2005-06-08 2006-12-14 Japan Tobacco Inc. Heterocyclic compound
JP4137956B2 (ja) 2005-06-08 2008-08-20 日本たばこ産業株式会社 複素環化合物
WO2007034279A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
TWI378922B (en) * 2005-10-21 2012-12-11 Mitsubishi Tanabe Pharma Corp A pyrazole compound
JP2009523748A (ja) 2006-01-18 2009-06-25 シエナ ビオテク ソシエタ ペル アチオニ α７ニコチン性アセチルコリン受容体の調節物質およびそれらの治療への使用
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
CA2675511A1 (en) * 2006-10-10 2008-04-17 Amgen Inc. N-aryl pyrazole compounds for use against diabetes
US20100144793A1 (en) 2006-11-24 2010-06-10 Ac Immune Sa Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
SG173409A1 (en) 2006-11-24 2011-08-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
JP4994295B2 (ja) * 2007-04-20 2012-08-08 田辺三菱製薬株式会社 医薬組成物
WO2009091813A1 (en) 2008-01-14 2009-07-23 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
EP2349484A2 (en) 2008-07-15 2011-08-03 Novartis AG Heteroaryl derivatives as dgat1 inhibitors
KR101955691B1 (ko) 2010-03-30 2019-03-07 베르선 코포레이션 트롬빈 억제제로서의 다중치환된 방향족 화합물
WO2011161615A1 (en) * 2010-06-24 2011-12-29 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
CN106922146B (zh) * 2014-10-02 2020-05-26 豪夫迈·罗氏有限公司 用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
SG11202009179TA (en) * 2018-04-04 2020-10-29 Japan Tobacco Inc Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof

Also Published As

Publication number Publication date
CO2020012353A2 (es) 2021-01-18
EP3778593A4 (en) 2021-12-22
CA3089092A1 (en) 2019-10-10
ZA202006053B (en) 2022-03-30
CN111902408A (zh) 2020-11-06
WO2019194207A1 (ja) 2019-10-10
EP3778593A1 (en) 2021-02-17
RU2020132318A (ru) 2022-04-29
MX2020010433A (es) 2020-10-28
CN111902408B (zh) 2023-11-14
IL277686A (en) 2020-11-30
AR114465A1 (es) 2020-09-09
JP2019182852A (ja) 2019-10-24
US20240166632A1 (en) 2024-05-23
TW201942114A (zh) 2019-11-01
US20190330193A1 (en) 2019-10-31
RU2020132318A3 (es) 2022-04-29
KR20200139696A (ko) 2020-12-14
US10988462B2 (en) 2021-04-27
TWI805727B (zh) 2023-06-21
JP7130588B2 (ja) 2022-09-05
PH12020551624A1 (en) 2021-07-12
JP2024050645A (ja) 2024-04-10
JP2022166280A (ja) 2022-11-01
BR112020019939A2 (pt) 2021-01-05
PE20201068A1 (es) 2020-10-19
AU2019249560A1 (en) 2020-07-23
SG11202009179TA (en) 2020-10-29
US20220048896A1 (en) 2022-02-17
AU2019249560B2 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
CL2020002550A1 (es) Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos.
UY37854A (es) Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
CY1120703T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
CO6852096A2 (es) Métodos plaguicidasque utilizan compuestos de 3-piridil tiazol sustituidos y derivados para combatir las plagas de animales i
PE20190395A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
AR074426A1 (es) Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende
RS54492B1 (en) KINASE INHIBITOR REGULATING THE SIGNAL PATH OF APOPTOSIS
CL2020000363A1 (es) Inhibidores macrocíclicos de mcl-1 y métodos de uso.
CR20160548A (es) Nuevos Derivados de Pirazolo Pirimidina y su Uso como Inhibidores de MALT1
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
BR112016016844A2 (pt) Compostos heterocíclicos
CL2019003857A1 (es) Composiciones y métodos de uso de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida solicitudes relacionadas.
CL2017002090A1 (es) Inhibidores selectivos de bace1
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
CL2017002354A1 (es) Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd.
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
CU20210023A7 (es) Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4
UY36124A (es) Derivados de carboxamida
MX2020003993A (es) Derivados de bencimidazol y sus usos.
UY36123A (es) Derivados de carboxamida